STOCK TITAN

PolarityTE to Report First Quarter Financial Results on May 13, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

PolarityTE, Inc. (Nasdaq: PTE) announced it will report Q1 2021 results on May 13, 2021, around 4:00 p.m. ET. A conference call, including a Q&A session, will follow at 4:30 p.m. ET, accessible via a dial-in or webcast. The earnings call replay will be available for 30 days on the company's website. PolarityTE focuses on developing regenerative tissue products and biomaterials from patients' own tissues, promoting healing through innovative methods. Investors should look out for the financial metrics and operational updates in the upcoming results.

Positive
  • Upcoming Q1 2021 earnings report scheduled for May 13, 2021.
  • Focus on regenerative tissue products presents potential growth opportunities.
Negative
  • Risks related to the COVID-19 pandemic and FDA regulatory matters could affect actual results.

PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time.

In addition, the Company will host a conference call and webcast with Q&A on May 13, 2021 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing 1-800-377-1217 (U.S. and Canada) or +44 (0)330 027 2386 (International) with confirmation code 231666 and referencing “PolarityTE First Quarter 2021 Earnings Call”. A webcast of the conference call can be accessed by using the link below.

Earnings Call Webcast – CLICK HERE

A replay of the earnings conference call will be available for 30 days, beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE’s website at https://www.polarityte.com/news-media/events, or by clicking on the link above.

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative methods are intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.

Forward Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

FAQ

When will PolarityTE report its Q1 2021 earnings?

PolarityTE will report its Q1 2021 earnings on May 13, 2021.

What time is the PolarityTE conference call for Q1 2021 results?

The conference call is scheduled for May 13, 2021, at 4:30 p.m. ET.

How can I access the PolarityTE earnings call?

The earnings call can be accessed by dialing 1-800-377-1217 or through a webcast available on their website.

What is the focus of PolarityTE's business?

PolarityTE focuses on developing regenerative tissue products and biomaterials from patients' own tissues.

What risks does PolarityTE mention in its press release?

The company mentions risks related to the COVID-19 pandemic and FDA regulatory matters that could impact results.

PTE

NASDAQ:PTE

PTE Rankings

PTE Latest News

PTE Stock Data

1.78M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Salt Lake City